Trial Profile
A Treatment Protocol for Extended Administration of Prometic Plasminogen (Human) by Intravenous Infusion in Subjects With Hypoplasminogenemia Requiring Plasminogen Replacement Therapy
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Plasminogen (Primary)
- Indications Type I plasminogen deficiency
- Focus Expanded access; Therapeutic Use
- Sponsors ProMetic BioTherapeutics
- 11 Feb 2020 Status changed from recruiting to completed.
- 29 Aug 2018 New trial record